Phase II study of Roche ’s giredestrant meets primary endpoint in the most frequently diagnosed type of breast cancer

Basel, 10 December 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase II coopERA Breast Cancer study met its primary endpoint in the neoadjuvant treatment of early stage ER-positive, HER2-negative breast cancer. Breast cancer is the most frequently diagnosed type of cancer, with major societal impac t.2 Hormone receptor (HR)-positive breast cancer is the most common subtype, representing ~70% of all diagnoses, or an estimated 1.6 million cases annually across the world.2,3
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news